{"product_id":"iva-vrio-analysis","title":"Inventiva S.A. (IVA): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Inventiva S.A. (IVA)'s market position with this concise VRIO analysis, where we rigorously test its core resources for Value, Rarity, Inimitability, and Organization. Discover immediately whether this business possesses a sustainable competitive advantage or if its strengths are easily replicated. Read on below to see the distilled verdict on what truly drives Inventiva S.A. (IVA)'s success.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eInventiva S.A. (IVA) - VRIO Analysis: 1. Lanifibranor Lead Asset Status\n\u003c\/h2\u003e\n\n\u003cp\u003eYou're looking at Inventiva S.A. (IVA) right now, and the entire story hinges on Lanifibranor, their oral therapy for MASH (Metabolic Dysfunction-Associated Steatohepatitis). The near-term action is simple: watch the clock for the Phase 3 readout, because that data is the key that unlocks everything else. As of mid-2025, the company has secured its runway to get there, but the clock is ticking toward the expected topline data in the \u003cstrong\u003esecond half of 2026\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eValue: It's a novel pan-PPAR agonist targeting MASH, a large market, and has completed enrollment for its pivotal Phase 3 trial, making it the primary value driver.\u003c\/h3\u003e\n\u003cp\u003eLanifibranor is targeting MASH, a condition with a massive and growing patient pool. The global market was already valued at \u003cstrong\u003eUSD 7.87 billion\u003c\/strong\u003e in 2024, projected to hit \u003cstrong\u003eUSD 31.76 billion\u003c\/strong\u003e by 2033, so the potential value is huge. The asset’s value is crystallized by the completion of enrollment in the NATiV3 Phase 3 trial as of April 1, 2025, enrolling \u003cstrong\u003e1009\u003c\/strong\u003e patients in the main cohort and \u003cstrong\u003e410\u003c\/strong\u003e in the exploratory cohort, exceeding targets. This late-stage progress, backed by the FDA’s Breakthrough Therapy designation, makes it a tangible asset, not just a concept. The company’s cash position as of June 30, 2025, stood at \u003cstrong\u003e€122.1 million\u003c\/strong\u003e in cash equivalents plus \u003cstrong\u003e€24.6 million\u003c\/strong\u003e in short-term deposits, which helps fund operations until the readout.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: A late-stage, oral small molecule for MASH is rare, especially one with demonstrated anti-inflammatory and anti-fibrotic effects.\u003c\/h3\u003e\n\u003cp\u003eHonestly, a late-stage, oral treatment for MASH is rare because the space is dominated by injectables or has only one approved drug, Rezdiffra (resmetirom), which was approved in early 2024. Lanifibranor’s mechanism as a pan-PPAR agonist, targeting inflammation and fibrosis simultaneously, gives it a distinct profile compared to single-target approaches. The fact that the NATiV3 trial has exceeded its enrollment goals suggests strong investigator interest in this differentiated profile. It’s rare to have a drug this far along with this specific combination of attributes.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: High, as the molecule itself is protected by patents, but the clinical data package is unique to them.\u003c\/h3\u003e\n\u003cp\u003eThe core molecule is protected by patents, which is standard for pharma, making the compound itself hard to copy directly. What’s truly inimitable right now is the entire clinical package - the data from the NATIVE Phase 2b trial and the ongoing NATiV3 Phase 3 trial. That specific set of patient responses, especially the consistency noted between the Phase 2b and NATiV3 baseline characteristics, is unique to Inventiva S.A.. If the Phase 3 results are positive, replicating that entire journey, including the FDA designation, is a multi-year, multi-hundred-million-dollar hurdle for any competitor.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Yes, the company has explicitly prioritized its entire focus and resources on this single asset as of mid-2025.\u003c\/h3\u003e\n\u003cp\u003eInventiva S.A. has made the necessary organizational moves to support this asset. They implemented a pipeline prioritization plan that stopped all preclinical research and reduced the workforce by \u003cstrong\u003e50%\u003c\/strong\u003e to focus exclusively on Lanifibranor’s development. This sharp focus means that nearly all operational and R\u0026amp;D spend - which was \u003cstrong\u003e(€45.2) million\u003c\/strong\u003e in H1 2025 - is directed here. They structured financing, bringing in \u003cstrong\u003e€104.9 million\u003c\/strong\u003e in net proceeds in H1 2025, specifically to see this trial through. They are organized around this one shot.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage: Sustained, provided the Phase 3 data, expected in H2 2026, is positive and the IP holds.\u003c\/h3\u003e\n\u003cp\u003eIf the NATiV3 trial delivers positive topline data in the \u003cstrong\u003esecond half of 2026\u003c\/strong\u003e, the advantage becomes sustained, at least temporarily. This is because the combination of a differentiated mechanism, late-stage validation, and the company’s singular organizational focus creates a high barrier for others to overcome quickly. The market is wide open, but only the first mover with compelling data secures the lion’s share of the initial value capture. The risk is that if the data disappoints, the advantage evaporates instantly.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n    \u003ctd\u003eAssessment\u003c\/td\u003e\n    \u003ctd\u003eCompetitive Implication\u003c\/td\u003e\n    \u003ctd\u003eScore (1-4)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eYes, addresses a multi-billion dollar, high unmet need market (MASH).\u003c\/td\u003e\n    \u003ctd\u003eCompetitive Parity \/ Potential Advantage\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eYes, late-stage, oral pan-PPAR agonist is rare in the current landscape.\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003eCostly and time-consuming to replicate the clinical package; molecule patented.\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eYes, 50% workforce reduction and dedicated financing to support the asset.\u003c\/td\u003e\n    \u003ctd\u003eSupport for Advantage\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOverall Advantage\u003c\/td\u003e\n    \u003ctd\u003eSustained Competitive Advantage (Contingent on Positive H2 2026 Readout)\u003c\/td\u003e\n    \u003ctd\u003ePotential for Market Leadership\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eN\/A\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eIf onboarding takes 14+ days, churn risk rises, but for Inventiva S.A., the real risk is the \u003cstrong\u003e72-week\u003c\/strong\u003e treatment period in NATiV3 before the data lands.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday, incorporating the \u003cstrong\u003e€104.9 million\u003c\/strong\u003e financing proceeds from H1 2025.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eInventiva S.A. (IVA) - VRIO Analysis: 2. Lanifibranor Patent Protection\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eLanifibranor Patent Protection Metrics\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Latest Patent Expiry\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2045\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncluding expected Patent Term Extension (PTE)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS Patent Expiry (Specific Use)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNovember 8, 2039\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCirrhotic patient treatment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS Patent Expiry (Specific Use)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJune 2035\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFibrotic diseases treatment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNumber of Granted Countries (Key Patents)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt; 50\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eComposition of matter and NASH patents\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 R\u0026amp;D Expense (Lanifibranor)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€90.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull year 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnalyst Peak Sales Estimate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.6 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAnnually (Jefferies, as of 2020)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Royalty Rate (Years 1-3)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eHigh single-digit to mid-teen double digits\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOn net sales in Japan\/South Korea\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides exclusivity, which is essential for recouping massive R\u0026amp;D costs and achieving premium pricing post-approval.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e A patent extending protection until 2045 is a significant, rare asset in the pharma space.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Very high; patents are legally protected barriers to entry.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The IP department is organized to maintain and defend this asset, which is critical for future commercialization.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; this is a legal moat.\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D expenses for Lanifibranor development in H1 2025 amounted to €44.9 million.\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D expenses in 2024 were €90.9 million, a 17% decrease compared to €110.0 million in 2023.\u003c\/p\u003e\n\u003cp\u003eThe company expects that the NASH patent will be selected for Patent Term Extension (PTE).\u003c\/p\u003e\n\u003cp\u003eRoyalty Certificates issued in July 2024 secured €20.1 million for holders, granting the right to an annual payment of royalties equal to 3% of potential future net sales of lanifibranor in the United States, the European Union, and the United Kingdom over a 14-year term from the date of issuance.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLanifibranor is the only pan-PPAR agonist in clinical development, activating all three PPAR isoforms in a moderately potent manner.\u003c\/li\u003e\n\u003cli\u003eThe composition of matter patent and NASH patent have been granted in \u0026gt; 50 countries including EP, US, CN, JP, KR, AU, CA, RU.\u003c\/li\u003e\n\u003cli\u003eRoyalty rates for the Hepalys agreement are tiered from high single-digit to mid-teen double digits on net sales during the first three years of commercialization and from low to mid-teen double digits starting from year four.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eInventiva S.A. (IVA) - VRIO Analysis: 3. NATiV3 Phase 3 Trial Enrollment Completion\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nEnrollment completion for the main cohort of \u003cstrong\u003e1009\u003c\/strong\u003e patients and the exploratory cohort of \u003cstrong\u003e410\u003c\/strong\u003e patients de-risks the timeline for the crucial data readout in the \u003cstrong\u003esecond half of 2026\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eCohort\u003c\/td\u003e\n\u003ctd\u003eTarget Enrollment\u003c\/td\u003e\n\u003ctd\u003eActual Enrollment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMain Cohort\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e969\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1009\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExploratory Cohort\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e350\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e410\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nAchieving full enrollment, exceeding targets of \u003cstrong\u003e969\u003c\/strong\u003e (main) and \u003cstrong\u003e350\u003c\/strong\u003e (exploratory) patients, is a rare operational success in drug development.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nModerate; competitors can start trials, but replicating this specific trial's progress is hard due to site setup and patient access.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nShows effective clinical operations and site management across Europe and North America, with recruitment active at 359 sites across 24 countries as of July 2024.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTopline results expected in the \u003cstrong\u003esecond half of 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe trial is designed for a 72-week treatment duration for the main cohort.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nTemporary; the advantage fades once the data is public, but it buys time now and satisfied conditions for the second tranche of structured financing of up to \u003cstrong\u003e€348 million\u003c\/strong\u003e, unlocking approximately \u003cstrong\u003e€116 million\u003c\/strong\u003e (gross proceeds of \u003cstrong\u003e€115.6 million\u003c\/strong\u003e) upon completion.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eInventiva S.A. (IVA) - VRIO Analysis: 4. CTTQ License Agreement \u0026amp; Milestone Payments\n\u003c\/h2\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThe CTTQ License Agreement provides non-dilutive funding and validation for lanifibranor in the Asian market, with Inventiva eligible to receive up to an additional $265 million in clinical, regulatory, and commercial milestone payments, plus royalties in the low single digits on annual net sales, if approved.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eOriginal Term (2022)\u003c\/th\u003e\n\u003cth\u003eAmended Term (Post-Oct 2024)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Milestones (Excl. Upfront\/Tranches)\u003c\/td\u003e\n\u003ctd\u003eUp to $40 million\u003c\/td\u003e\n\u003ctd\u003eUp to $265 million (Additional)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties (Years 1-3)\u003c\/td\u003e\n\u003ctd\u003eHigh single-digit to mid-teen double digits\u003c\/td\u003e\n\u003ctd\u003eLow single digits\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties (Year 4+)\u003c\/td\u003e\n\u003ctd\u003eLow to mid-teen double digits\u003c\/td\u003e\n\u003ctd\u003eLow single digits\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eA licensing partnership with a significant player like CTTQ, a subsidiary of Sino Biopharm, for the development and commercialization of lanifibranor in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, and Taiwan, is valuable, though similar deals occur in the industry.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eThe specific terms of the amended agreement are unique, particularly the structure tied to the Structured Financing tranches. The company received a $10 million milestone payment in July 2025.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe $10 million payment in July 2025 followed the settlement of the second tranche of the structured financing, which was €115.6 million gross proceeds (€108.5 million net proceeds).\u003c\/li\u003e\n\u003cli\u003eThe total of $30 million in milestones related to the equity financing was structured across three payments tied to the financing tranches and topline data publication.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eThe business development team successfully executed the management of the CTTQ License Agreement, including invoicing and securing the $10 million milestone payment received in July 2025. CTTQ also joined Inventiva's ongoing NATiV3 pivotal Phase 3 clinical trial, which includes over 60 sites across mainland China.\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eThe value is currently realized through the non-dilutive cash infusion, such as the $10 million received in July 2025. The potential for future milestones, up to $265 million remaining, is the primary driver of the current advantage, which is subject to future clinical and regulatory success.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eInventiva S.A. (IVA) - VRIO Analysis: 5. Cash Position and Recent Financing\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The capital base funds operations through the critical data readout period, reducing immediate financing pressure.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The ability to raise significant capital recently is key; they secured net proceeds of approximately \u003cstrong\u003e€139.3 million\u003c\/strong\u003e in a November 2025 public offering.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; competitors can raise money, but the timing and terms of this specific raise are unique to their situation.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Finance and Investor Relations successfully executed the November 2025 offering, extending the cash runway to the end of \u003cstrong\u003eQ1 2027\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this cash buffer is finite and will be spent on R\u0026amp;D.\u003c\/p\u003e\n\n\u003cp\u003eThe financial position was significantly bolstered by the November 2025 capital raise, as detailed below:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAs of September 30, 2025 (Pre-Financing)\u003c\/th\u003e\n\u003cth\u003ePost-November 2025 Offering\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€97.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShort-Term Deposits\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€24.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Cash Runway\u003c\/td\u003e\n\u003ctd\u003eEnd of \u003cstrong\u003eQ3 2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eEnd of \u003cstrong\u003eQ1 2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Net Proceeds from Offering\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e€139.3 million\u003c\/strong\u003e ($161.2 million)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Proceeds from Offering\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$172.5 million\u003c\/strong\u003e (€149.0 million)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFurther details regarding the financing and the cash position include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal American Depositary Shares (ADSs) issued in the Offering: \u003cstrong\u003e44,805,193\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOffering Price per ADS: \u003cstrong\u003e$3.85\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRevenue recognized for the first nine months of 2025: \u003cstrong\u003e€4.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eInventiva S.A. (IVA) - VRIO Analysis: 6. Proprietary Scientific Platform (Nuclear Receptor Modulation)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e This deep, specialized knowledge base allows them to design and optimize small molecules targeting complex pathways like fibrosis and metabolic dysfunction.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; the specific combination of medicinal chemistry, pharmacology, and translational science expertise in this niche is not common.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; it’s tacit knowledge built over years, not easily copied from a manual.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e This platform is the engine that generated lanifibranor and other pipeline candidates.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; this is a core, hard-to-replicate competency.\u003c\/p\u003e\n\u003cp\u003eThe platform's output and underlying assets are quantified by the following metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLanifibranor is the only pan PPAR agonist in clinical development, activating all three peroxisome proliferator activated receptor (PPAR) isoforms in a moderately potent manner, with a well balanced activation of PPAR$\\alpha$ and PPAR$\\delta$, and a partial activation of PPAR$\\gamma$.\u003c\/li\u003e\n\u003cli\u003eThe Company owns a proprietary chemical library of over 240,000 molecules.\u003c\/li\u003e\n\u003cli\u003eThe scientific team comprises approximately 90 people with deep expertise in the fields of biology.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProprietary Molecules in Library\u003c\/td\u003e\n\u003ctd\u003eOver 240,000\u003c\/td\u003e\n\u003ctd\u003eAs of late 2022\/2019\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e€90.9 million\u003c\/td\u003e\n\u003ctd\u003eFull year 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e€96.6 million\u003c\/td\u003e\n\u003ctd\u003eAs of December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLanifibranor US Patent Expiration (Fibrotic Diseases)\u003c\/td\u003e\n\u003ctd\u003eJune 2035\u003c\/td\u003e\n\u003ctd\u003eGranted August 20, 2019\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLanifibranor Patent Expiration (Cirrhosis)\u003c\/td\u003e\n\u003ctd\u003eNovember 8, 2039\u003c\/td\u003e\n\u003ctd\u003eGranted late 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe platform's organization is evidenced by its financial commitment and intellectual property protection:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eR\u0026amp;D expenses for the full year 2024 amounted to €90.9 million.\u003c\/li\u003e\n\u003cli\u003eThe Company closed the first tranche of up to €348 million structured financing with aggregate gross proceeds of €116 million.\u003c\/li\u003e\n\u003cli\u003eRoyalty Certificates were issued for approximately €20.1 million in July 2024, granting holders the right to 3% of potential future net sales of lanifibranor.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eInventiva S.A. (IVA) - VRIO Analysis: 7. Focused Pipeline Prioritization Strategy\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Focus exclusively on lanifibranor in H1 2025; workforce reduced by approximately \u003cstrong\u003e50%\u003c\/strong\u003e. Cash and cash equivalents as of December 31, 2024, were \u003cstrong\u003e€96.6 million\u003c\/strong\u003e. Cash and cash equivalents as of September 30, 2025, were \u003cstrong\u003e€97.6 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Strategic decision to terminate preclinical programs:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eYAP-TEAD program\u003c\/li\u003e\n\u003cli\u003eNR4A1 program\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Strategic organizational decision, not a replicable physical asset.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Implementation discipline reflected in R\u0026amp;D expenses:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeriod\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (€ million)\u003c\/td\u003e\n\u003ctd\u003eYear-over-Year Change\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFirst Nine Months (9M) 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e(64.6)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSlightly lower by \u003cstrong\u003e11%\u003c\/strong\u003e compared to 9M 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe workforce reduction started to take effect on May 23, 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; efficiency realized through resource reallocation.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eInventiva S.A. (IVA) - VRIO Analysis: 8. Dual-Listing and US Capital Market Access\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Listing on Nasdaq (ticker: IVA) provides access to a deeper pool of US-based institutional and retail biotech investors, crucial for large-scale funding. The dual-listing structure supported a November 2025 underwritten public offering of American Depositary Shares (ADSs) that was upsized to gross proceeds of approximately \u003cstrong\u003e$172.5 million\u003c\/strong\u003e. This capital raise, priced at \u003cstrong\u003e$3.85\u003c\/strong\u003e per ADS, was intended to fund the continuation of the NATiV3 Phase 3 clinical trial for lanifibranor.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Being dual-listed on Euronext Paris and Nasdaq is a strategic advantage for a European firm. The company's ordinary shares are listed on Euronext Paris, and its ADSs trade on the Nasdaq Global Market under the ticker \u003cstrong\u003eIVA\u003c\/strong\u003e. The initial Nasdaq IPO date was \u003cstrong\u003eJul 10, 2020\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; establishing a US listing and maintaining compliance is a known but resource-intensive process. The structure facilitates US-centric financing activities, such as the November 2025 offering, which involved filing a shelf registration statement on Form F-3 with the SEC.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The US subsidiary and dual listing structure facilitate US-centric financing activities, like the November 2025 ADS offering. Trading on Euronext Paris was temporarily halted on November 13, 2025, to allow for the pricing and allocation of the US offering, resuming later that day at 4:30 p.m. CET.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; the established listing and investor base are sticky resources. The success of the November 2025 offering, where the initial planned raise of approximately \u003cstrong\u003e$125 million\u003c\/strong\u003e was increased due to underwriter option exercise, demonstrates the market's confidence in the US capital market access.\u003c\/p\u003e\n\n\u003cp\u003eThe following table summarizes key financial and market data relevant to the dual-listing and recent capital activity:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Gross Proceeds from Nov 2025 ADS Offering\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$172.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFinal amount after option exercise (Nov 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Planned Offering Size\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$125 million\u003c\/strong\u003e (approx. \u003cstrong\u003e€108 million\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eNovember 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNumber of New ADSs Issued (Initial)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e38,961,038\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNovember 2025 Offering\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOffering Price Per ADS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.85\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNovember 2025 Offering\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents (as of Sep 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€97.61 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePre-offering balance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShort-Term Deposits (as of Sep 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€24.71 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePre-offering balance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$768.00M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of December 07, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNasdaq Listing Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJul 10, 2020\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIPO Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e52-Week Trading Range (ADS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.1112 \/ $7.9825\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of December 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnalyst Consensus (9 Analysts)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eStrong Buy\u003c\/strong\u003e \/ \u003cstrong\u003eVery Bullish\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eRecent Rating\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eInventiva S.A. (IVA) - VRIO Analysis: 9. Cash Position as of September 30, 2025\n\u003c\/h2\u003e\n\n\u003ch\u003eValue: Provides a concrete measure of immediate operational solvency before the November financing impact.\u003c\/h\u003e\n\u003cp\u003eAs of September 30, 2025, Inventiva held \u003cstrong\u003e€97.6 million\u003c\/strong\u003e in cash and cash equivalents and \u003cstrong\u003e€24.7 million\u003c\/strong\u003e in short-term deposits.\u003c\/p\u003e\n\n\u003ch\u003eRarity: The specific amount is a hard number reflecting their current state.\u003c\/h\u003e\n\u003cp\u003eThe specific amounts of \u003cstrong\u003e€97.6 million\u003c\/strong\u003e in cash and cash equivalents and \u003cstrong\u003e€24.7 million\u003c\/strong\u003e in short-term deposits are a precise reflection of the balance sheet at that date.\u003c\/p\u003e\n\n\u003ch\u003eImitability: Low; this is a historical accounting fact.\u003c\/h\u003e\n\u003cp\u003eThe reported figures are historical accounting facts, making them inherently low in imitability as they represent past transactions.\u003c\/p\u003e\n\n\u003ch\u003eOrganization: The finance team accurately tracks and reports this, showing control over the balance sheet.\u003c\/h\u003e\n\u003cp\u003eThe reporting of detailed financial metrics, including the cash position and cash flow statement components, demonstrates organizational control over financial tracking.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage: Temporary; this number is constantly changing, but as of Sept 30, 2025, they held €97.6 million in cash and €24.7 million in short-term deposits.\u003c\/h\u003e\n\u003cp\u003eThe competitive advantage derived from this specific cash level is temporary, as the figure is subject to immediate change based on ongoing operations and financing activities.\u003c\/p\u003e\n\n\u003cp\u003eThe operational cash usage and financing activities for the first nine months of 2025 compared to the same period in 2024 are detailed below:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric (9 Months Ended September 30)\u003c\/td\u003e\n\u003ctd\u003e2025 Amount\u003c\/td\u003e\n\u003ctd\u003e2024 Amount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€4.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNot explicitly stated in comparison\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet cash used in operating activities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e(€76.3) million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e(€63.7) million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e(€64.6) million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e11% higher than 9M 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet cash generated from financing activities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€103.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e€41.9 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFurther details on the cash position evolution:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and cash equivalents as of September 30, 2025, were \u003cstrong\u003e€97.6 million\u003c\/strong\u003e, compared to \u003cstrong\u003e€96.6 million\u003c\/strong\u003e as of December 31, 2024.\u003c\/li\u003e\n\u003cli\u003eNet cash used in operating activities for the first nine months of 2025 was \u003cstrong\u003eup by 20%\u003c\/strong\u003e compared to the same period in 2024.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D expenses for the first nine months of 2025 were \u003cstrong\u003eslightly lower by 11%\u003c\/strong\u003e compared to the same period in 2024.\u003c\/li\u003e\n\u003cli\u003eNet cash generated from financing activities for the first nine months of 2025 was \u003cstrong\u003e€103.4 million\u003c\/strong\u003e, compared to \u003cstrong\u003e€41.9 million\u003c\/strong\u003e in the same period in 2024.\u003c\/li\u003e\n\u003cli\u003eThe cash runway is expected until the end of the first quarter of 2027, including net proceeds from the November 2025 public offering.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516190580885,"sku":"iva-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/iva-vrio-analysis.png?v=1740185929","url":"https:\/\/dcf-model.com\/pt\/products\/iva-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}